| |
| 302 | | A cross-sectional review of the presenting ocular features of Behçet’s disease in patients from a single centre in the UK | | SINGH A, SREEKANTAM S, SITUNAYAKE D, CHANDRATRE P, TOSOUNIDOU S, BASKER S, MURRAY P, RICHARDS A, POVEDA-GALLEGO A, HIGHAM J |
| |
| |
| 305 | | Clinical pattern of retinitis in Behçet disease | | ALLAGUI O, KECHIDA M, BEN KHLIFA S, WALHA Y, KSIAA I, KHAIRALLAH M |
| 306 | | Sex-specific unconventional neutrophils determine immunological outcome in Behçet's uveitis | | WANG QF, GAO Y, YANG PZ |
| 307 | | This association of Behcet disease and HLA B27 | | REGAI E, ZAYANI M, BEN SALEM M, BEN SALEM Y, FAKHOURI A, ABADA S |
| 308 | | Tinnitus as a potential risk factor for uveitis: A Nationwide Population-based cohort study in Taiwan. | | LIN CJ, CHEN YJ, HSU A, HSIA NY, MENG PP, LIAO PL, HSU MY, LAI CT, CHEN HS, TSAI YY |
| 309 | | EVALUATION OF INFLAMMATORY CYTOKINES IN THE UVEITIC GLAUCOMA | | MEDJIDOVA S.R. |
| 310 | | Inflammatory IOL opacification | | MONTERO-MORENO J, DIEZ-MONTERO C, SANCHIS-MERINO ME, GONZALEZ-URUENA C, HERNANDEZ-FERNANDEZ R, CAñIBANO-PEREZ E |
| 311 | | What affects the outcome of cataract surgery in patients with uveitis? | | JEVNIKAR K, POčKAR Saša, UMEK Lan, ROTHOVA A, VIDOVIč VALENTINčIč N |
| |
| 313 | | Machine learning-based diagnosis of uveitis diseases using routine peripheral blood test data | | TSUBOTA K, USUI Y, NEZU N, GOTO H |
| 314 | | Cytokines profile in ocular fluid of patients with uveitis: preliminary results | | FERRACIOLI-ODA E, COELHO V, TANAKA T, GOUVEIA MGS, PINHO JR, BISPO PJ, HIRATA CE, ANTONANGELO L, YAMAMOTO JH |
| 315 | | Diagnostic Aqueous Sampling at University Hospital Southampton for Infectious Retinitis | | KALOGEROPOULOS D, RAHMAN N, KAHN A, HALL N, AFSHAR F |
| 316 | | Histopathology, immunohistochemistry and molecular biologic study of eviscerated / enucleated specimen of end-stage ocular inflammatory diseases. | | BISWAS J, PATNAIK G |
| 317 | | I survived cancer, now I can’t see | | TOUMANIDOU V, RIRI K, LAZARI C, CHADOULOS N, ANDROUDI S |
| |
| 319 | | Association study of KIR genes with sarcoidosis in a Japanese population | | MEGURO A, TAKEUCHI M, ISHIHARA M, MIZUKI N |
| 320 | | Comprehensive microRNA analysis using vitreous humor of ocular sarcoidosis patients | | ASAKAGE M, USUI Y, NEZU N, SHIMIZU H, TSUBOTA K, YAMAKAWA N, TAKANASHI M, KURODA M, GOTO H |
| 321 | | Ocular Sarcoidosis: long term experience of an Italian referral center. | | RISSOTTO R, ALLEGRI P, RISSOTTO F |
| 322 | | World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) Sarcoidosis Organ Assessment Instrument Use in the Analysis of a Retrospective Sarcoidosis Cohort | | LEVY-CLARKE G, SADAT O, PINION C |
| 323 | | Retinal Granulomas in Ocular Sarcoidosis: An Under-recognized Phenomena | | RISSOTTO F, MISEROCCHI E, GOLDSTEIN D, ZICARELLI F, INVERNIZZI A, PICHI F, MARCHESE A |
| 325 | | Paravenous pigmented chorioretinal atrophy associated with iris atrophy in presumed sarcoidosis uveitis : A case report | | KSIAA I, TRIMECHE E, ABROUG N, BEN MOULA A, BESSAIDI O, KHAIRALLAH M |
| 326 | | Ocular sarcoidosis and macular edema | | FERREIRA C, COSTA S, FIGUEIRA L |
| 327 | | A Case Report on Sympathetic Ophthalmia in a Delayed Repair of a Ruptured Globe Following Blunt Ocular Trauma | | ARRIOLA LK, ONG LR, DIONSON M |
| 328 | | Sympathetic ophthalmia treated by intravitreal aflibercept | | MONTERO-MORENO J, DIEZ-MONTERO C, SANCHIS-MERINO ME, GONZALEZ-URUENA C, HERNANDEZ-FERNANDEZ R, CAñIBANO-PEREZ E |
| 331 | | Successful Intravenous Steroid Therapy in Exacerbated Sympathetic Ophthalmia | | APRILANI DA, SOFIA O |
| 332 | | Nitro-Oleic Acid Attenuates Inflammasome Activation and Exerts Cytoprotective Effects in Retinal Pigment Epithelial Cells: Implications for Uveitis Treatment | | CHANG YC, CHEN KJ, KAO TE, KAO YH, LEE DY |
| 333 | | Photobiomodulation (PBM) with Near Infrared Light (670 nm) Provides Anti-Inflammatory and Anti-Apoptotic Effects in a Rat Model of Endotoxin-Induced Uveitis (EIU). | | LIU P.K., CHEN T.W., WEN Y.T., TSAI R.K. |
| 334 | | Eye histological structure in non-infectious anterior and intermediate uveitis without and with neuroprotective therapy in late term (experimental study) | | ZBOROVSKA O, ULIANOV V, MALTSEV E, HORIANOVA I |
| 335 | | The effect of sulfasalazine on the course of recurrent anterior uveitis: a three-year follow-up. | | AVELLO GOROSTIDI A, HERNANZ RODRIGUEZ I, CARREÑO SALAS E |
| 336 | | Efficacy of Janus activated kinase (JAK) inhibitors in the treatment of ocular autoimmune disorders | | RüBSAM Anne, POHLMANN Dominika, ZUR BONSEN Lynn, PLEYER Uwe |
| 337 | | The fluocinolone acetonide (Iluvien) intravitreal implant in Non-Infectious Uveitis (NIU). A single-centre audit. | | RIGA V, RAMSEWAK S, BRAITHWAITE T, VIRGO J |
| 338 | | Real-life experience of Fluocinolone Acetonide Implant (Iluvien®) in non-infectious uveitic macular edema | | TOUHAMI S, JABBOUR M, ROUGIER MB, SERRAR Y, KODJIKIAN L, MAZHAR D, WEBER M, PEREZ-ROUSTIT S, CHIQUET C, BODAGHI B |
| 339 | | "Can simvastatin significantly reduce the amount of immunosuppressive medications required by patients with sight-threatening uveitis?" A phase IIb, single site, randomised, placebo-controlled, double-masked trial. | | AL-JANABI A, SHARIEF L, AL QASSIMI N, CHEN1 Y, AMBLER G, LADAS D, LIGHTMAN S, TOMKINS-NETZER O |
| 341 | | Three-years single-centre outcomes in Uveitis patients treated with fluocinolone acetonide intravitreal implant (ILUVIEN®) | | BALASUBRAMANIAN B, SHAH H, KARPOOR M, AGOROGIANNIS G, DENNISTON A K |
| 342 | | Steroid-sparing effect of Adalimumab monotherapy in non-infectious uveitis | | HARADA Y, HIYAMA T, SADA I, KIUCHI Y |
| 343 | | Long-term effects of tocilizumab on retinal and choroidal inflammation in refractory non-infectious uveitis | | ZUR BONSEN LS, SCHULZE D, KüNZEL S, RüBSAM A, PLEYER U, POHLMANN D |
| 344 | | Long-term outcomes and risk factors for prognosis in elective and non-elective vitrectomies for uveitis patients | | TASIOPOULOU A, CHEN YH, LAVNISH J, LIGHTMAN S, TOMKINS-NETZER O |
| 345 | | Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Survey Among Early-Adopting Physicians | | EMAMI P, XIPERE EARLY ADOPTERS SURVEY PARTICIPANTS - |
| 346 | | THE LONG-ACTING FLUOCINOLONE INTRAVITREAL IMPLANT EFFECT ON NON-INFECTIOUS UVEITIS: UNICENTER ANALYSIS FROM PORTUGAL | | CORREIA M, BAPTISTA M, MADEIRA MF, ROMANA J, CORDEIRO M, GUEDES M |
| 347 | | Non-infectious uveitis treated with 0,19 mg fluocinolone acetonide intravitreal implant (ILUVIEN®): a real-world case series | | BESELGA D, MARTINS L, RIBEIRO MJ, BORGES B, PEDROSA C, MARREIROS M, FRANCISCO D, PORTELA D |
| 348 | | Long-term Follow-up after Cryotherapy for Snowbanking in a Tertiary Care Center in Belgium | | WOUTERS M, DEPLA J, SCHAUWVLIEGHE PP |
| |
| 350 | | COMBINATION OF INTRAVITREAL STEROID IMPLANTS_A RESCUE STRATEGY FOR THE TREATMENT OF CHRONIC PANUVEITIS | | FURTADO MJ |
| 351 | | Management of inflammatory macular edema (ME) with ILUVIEN and top up triamcinolone (TCA) injections | | GOUVEIA P, GENTIL R |
| 352 | | TET2-mediated upregulation of 5-hydroxymethylcytosine in LRRC39 promoter promotes Th1 responses in Vogt-Koyanagi-Harada disease | | ZHANG WY, YANG PZ |
| 353 | | Transcriptomic profiling of iris tissue highlights B cell-mediated immunity in Vogt-Koyanagi-Harada disease | | DENG Y, YANG P |
| 354 | | Cost-Effectiveness Analysis of Adalimumab Versus Cyclosporine for Vogt-Koyanagi-Harada Disease | | DAI LY |
| 355 | | HLA-DR*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors | | TAKEUCHI M, MEGURO A, CHIKAGAWA R, OSADA R, SHIBUYA E, HASUMI Y, ISHIHARA M, MIZUKI N |
| 356 | | Therapeutic window of opportunity in the acute uveitic phase of Vogt-Koyanagi- Harada disease: prevention of late autoimmune complications by early intervention | | ABU EL-ASRAR A, AL RASHED F, AL BLOUSHI A, TOBAIGY M, GIKANDI P, HERBORT C, OPDENAKKER G |
| 357 | | Incidence of and Predictive Factors for Remission among Patients with Early Vogt-Koyanagi-Harada (VKH) Disease Treated with Systemic Corticosteroids and Conventional Immunosuppression | | PHINITKITANAN P, SITTIVARAKUL W |
| 358 | | Acute visual disturbance in chronic Vogt-Koyanagi-Harada (VKH) disease | | HUANG J, YEUNG L |
| 359 | | Epigenome-wide association study identifies Vogt-Koyanagi-Harada disease-associated DNA methylation loci in Chinese | | SU G, DU L, YANG P |
| 360 | | Effect of immunosuppressive therapy on ocular blood flow in initial-onset acute uveitis associated with Vogt–Koyanagi–Harada disease | | ABU EL-ASRAR A, AL SARHANI W, AL ZUBAIDI A, GIKANDI P |
| 361 | | Cyclosporine versus adalimumab added to corticosteroids for Vogt-Koyanagi-Harada disease | | ZHONG Z, DAI L, WU Q, GAO Y, PU Y, SU G, LU X, ZHANG F, TANG C, YANG P |
| 362 | | Vogt-Koyanagi-Harada in United Arab Emirates | | SATURNO M.C., ALJNEIBI S., NERI P., PICHI F. |
| 364 | | Association of disease control and clinical outcomes in Vogt-Koyanagi-Harada disease in a Chinese population | | LUI MH, YIM KL, LEUNG WY, YANG N |
| 365 | | Treatment Outcomes of Adalimumab Therapy in Vogt-Koyanagi-Harada Disease Patients in a Philippine Hospital: A Case Series | | OCAMPO VV, ALCALA MF |
| 366 | | Vogt-Koyanagi-Harada disease following a serology-proven Bartonella henselae retinitis: a case report | | KHAIRALLAH Molk, NABI Wejd, AMMARI Wafa, BEN SAIDI Ouss, ABROUG Nesr, KHAIRALLAH Monc |
| 367 | | Vogt-Koyanagi-Harada Syndrome induced by pembrolizumab in a patient with metastatic lung adenocarcinoma | | MENEZO V, AICHNER H, MOYA I |
| 369 | | An acute zonal occult outer retinopathy associated with a VKH syndrome : a case report | | GARGOURI M-A, SI LARBI S, AZAR G, FARES S, COCHEREAU I, TITAH C, TOUTAIN K |
| 370 | | Nivolumab induced Vogt-Koyanagi-Harada Syndrome managed with fluocinolone acetonide intravitreal implants: a case report | | MACHADO T, SIMõES J, FONSECA C |